Schramm W M, Papousek A, Michalek-Sauberer A, Czech T, Illievich U
Department of Anesthesiology and General Intensive Care, University of Vienna, Austria.
Anesth Analg. 1998 Jan;86(1):123-7. doi: 10.1097/00000539-199801000-00025.
Drugs for neurosurgical patients should not increase intracranial pressure (ICP) or change cerebral perfusion pressure (CPP) and cerebral blood flow. This double-blind, cross-over study compares the effects of a single (3 x effective dose producing 95% twitch depression) intravenous bolus dose of cisatracurium 0.15 mg/kg with atracurium 0.75 mg/kg on mean red blood cell flow velocity in the middle cerebral artery (CBFV; transcranial Doppler), ICP (intraventricular or intraparenchymal monitor), mean arterial pressure (MAP), CPP (MAP-ICP), and heart rate (HR) every minute during a 15-min study period. Included in the study were 14 sedated and ventilated adult neurosurgical patients. After the cisatracurium bolus, ICP, CPP, CBFV, MAP, and HR did not change, and no histamine related events were observed. After the atracurium bolus, ICP, CPP, CBFV, and MAP decreased. The lowest values of ICP (-16% of baseline), CPP (-5%), CBFV (-8%), and MAP (-7%) were recorded 2-4 min after the atracurium bolus injection. After this transient decrease, MAP and CPP returned to baseline, whereas CBFV and ICP transiently exceeded baseline values. The highest values of CBFV (5%) and ICP (17%) were recorded 9-12 min after the atracurium bolus injection. Five patients showed a typical histamine response after atracurium, with a decrease in MAP and flushing. Excluding these five patients eliminated statistical significance in ICP, CPP, CBFV, and MAP differences. In conclusion, cisatracurium demonstrated fewer cerebral and cardiovascular hemodynamic side effects in sedated adult neurosurgical patients.
This double-blind study in sedated and mechanically ventilated adult neurosurgical patients demonstrates that an intravenous bolus dose of the neuromuscular blocker cisatracurium results in less cerebral (intracranial pressure, cerebral perfusion pressure, middle cerebral artery blood flow velocity) and cardiovascular (blood pressure) hemodynamic side effects, compared with an equipotent dose of atracurium.
用于神经外科患者的药物不应增加颅内压(ICP)或改变脑灌注压(CPP)及脑血流量。这项双盲、交叉研究比较了单次静脉推注剂量的顺式阿曲库铵0.15mg/kg(3倍有效剂量,可产生95%的颤搐抑制)与阿曲库铵0.75mg/kg对大脑中动脉平均红细胞流速(CBFV;经颅多普勒)、ICP(脑室内或脑实质内监测仪)、平均动脉压(MAP)、CPP(MAP - ICP)以及心率(HR)在15分钟研究期间每分钟的影响。该研究纳入了14名接受镇静和机械通气的成年神经外科患者。静脉推注顺式阿曲库铵后,ICP、CPP、CBFV、MAP和HR均未改变,且未观察到与组胺相关的事件。静脉推注阿曲库铵后,ICP、CPP、CBFV和MAP下降。阿曲库铵推注后2 - 4分钟记录到ICP(-16%基线值)、CPP(-5%)、CBFV(-8%)和MAP(-7%)的最低值。在这种短暂下降后,MAP和CPP恢复到基线水平,而CBFV和ICP短暂超过基线值。阿曲库铵推注后9 - 12分钟记录到CBFV(5%)和ICP(17%)的最高值。5名患者在使用阿曲库铵后出现典型的组胺反应,MAP下降且面部潮红。排除这5名患者后,ICP、CPP、CBFV和MAP差异的统计学意义消失。总之,在接受镇静的成年神经外科患者中,顺式阿曲库铵表现出较少的脑和心血管血流动力学副作用。
这项针对接受镇静和机械通气的成年神经外科患者的双盲研究表明,与等效剂量的阿曲库铵相比,静脉推注神经肌肉阻滞剂顺式阿曲库铵导致的脑(颅内压、脑灌注压、大脑中动脉血流速度)和心血管(血压)血流动力学副作用更少。